BIIL 284 reduces neutrophil numbers but increases P

Slides:



Advertisements
Similar presentations
Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGB1) between inflammation and infection 
Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 
Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin  E.J. Growcott, A. Coulthard,
Alveolar inflammation in cystic fibrosis
Azithromycin fails to reduce increased expression of neutrophil-related cytokines in primary-cultured epithelial cells from cystic fibrosis mice  Ximena.
Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a Cystic Fibrosis patient  Joshua R. Stokell, Raad Z. Gharaibeh, Todd R.
The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis  Rana Herro, Ricardo Da S. Antunes, Amelia R. Aguilera,
Christopher C. Miller, Christopher A
Highlights of a workshop to discuss targeting inflammation in cystic fibrosis  Katharine H. Banner, Hugo De Jonge, Stuart Elborn, Ellena Growcott, Erich.
Neil E. Alexis, Marianne S. Muhlebach, David B. Peden, Terry L. Noah 
Lael M. Yonker, Cristina Cigana, Bryan P. Hurley, Alessandra Bragonzi 
Immunomodulatory activity of vardenafil on induced lung inflammation in cystic fibrosis mice  Bob Lubamba, François Huaux, Jean Lebacq, Etienne Marbaix,
IL-22 exacerbates weight loss in a murine model of chronic pulmonary Pseudomonas aeruginosa infection  Hannah K. Bayes, Neil D. Ritchie, Christopher Ward,
Effect of Aspergillus fumigatus and Candida albicans on pro-inflammatory response in cystic fibrosis epithelium  James A. Reihill, John E. Moore, J. Stuart.
Use of high-dose ibuprofen in a pediatric cystic fibrosis center
A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis  Emer P. Reeves, David A. Bergin, Sean Fitzgerald, Elaine.
Lactate in cystic fibrosis sputum
Development of a quantitative immunofluorescence assay for detection of Stenotrophomonas maltophilia antibodies in patients with cystic fibrosis  P. Gonçalves.
Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGB1) between inflammation and infection 
Volume 22, Issue 13, Pages (March 2018)
Andrew J. Ghio, Victor L. Roggli, Joleen M. Soukup, Judy H
Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model  K. Thomsen, L. Christophersen, T. Bjarnsholt, P.Ø.
Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy
Cirrhosis and other liver disease in cystic fibrosis
Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin 
Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection  Marita Gilljam, Henrik Scherstén, Martin Silverborn, Bodil.
Pro-inflammatory effect of cystic fibrosis sputum microparticles in the murine lung  Chiara Porro, Sante Di Gioia, Teresa Trotta, Silvia Lepore, Maria.
Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia  P.Ø. Jensen, C. Moser, A. Kharazmi,
Vaccination of Mice Against H pylori Induces a Strong Th-17 Response and Immunity That Is Neutrophil Dependent  Elizabeth S. DeLyria, Raymond W. Redline,
Fiona K. Dunlevy, S. Lorraine Martin, Francine de Courcey, J
Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations  Melanie Chin, Maya De Zoysa, Robert.
Expression of the inflammatory regulator A20 correlates with lung function in patients with cystic fibrosis  Catriona Kelly, Mark T. Williams, J. Stuart.
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study  Christine Rønne.
Early inflammation in the airways of a cystic fibrosis foetus
Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn 
Implementation of European standards of care for cystic fibrosis ��� Control and treatment of infection  J.S. Elborn, M. Hodson, C. Bertram  Journal of.
Interferon response of the cystic fibrosis bronchial epithelium to major and minor group rhinovirus infection  Aline Schögler, Andrea B. Stokes, Carmen.
P. aeruginosa drives CXCL8 synthesis via redundant toll-like receptors and NADPH oxidase in CFTR∆F508 airway epithelial cells  Lucie Roussel, Guy Martel,
Vitamin A and lung function in CF
The Loss of MCP-1 Attenuates Cutaneous Ischemia–Reperfusion Injury in a Mouse Model of Pressure Ulcer  Yuki Saito, Minoru Hasegawa, Manabu Fujimoto, Takashi.
Molecular Therapy - Nucleic Acids
A.H. Gifford  Journal of Cystic Fibrosis 
Oxidized glutathione and uric acid as biomarkers of early cystic fibrosis lung disease  Nina Dickerhof, Rufus Turner, Irada Khalilova, Emmanuelle Fantino,
Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis  Elizabeth F. Shead, Charles S. Haworth,
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
Methylomic correlates of autophagy activity in cystic fibrosis
Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis  D.W. Reid, R. Latham, I.L.
Christiane I. -U. Chen, Susanne Schaller-Bals, Karl P
Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J
Cytokine gene polymorphisms and severity of CF lung disease
Mukesh Kumar, PhDa, Aruna K. Behera, PhDa, Jianan Hu, MDa, Richard F
Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis  K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis  Geraint B. Rogers, Lucas R. Hoffman,
Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire  Joän M. Patterson, Melanie Wall, Jerica.
Volume 24, Issue 10, Pages (October 2016)
Stability of interleukin 8 and neutrophil elastase in bronchoalveolar lavage fluid following long-term storage  Luke J. Berry, Barbara Sheil, Luke Garratt,
Soluble inflammation markers in nasal lavage from CF patients and healthy controls  Natalie Beiersdorf, Matthias Schien, Julia Hentschel, Wolfgang Pfister,
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
Volume 34, Issue 5, Pages (May 2011)
Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid 
C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T
IL-10–treated dendritic cells decrease airway hyperresponsiveness and airway inflammation in mice  Toshiyuki Koya, MD, PhD, Hiroyuki Matsuda, MD, PhD,
Airway inflammation in mild cystic fibrosis
Brian S. Murphy, Heather M
Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern? 
Inhibition of allergic airways inflammation and airway hyperresponsiveness in mice by dexamethasone: Role of eosinophils, IL-5, eotaxin, and IL-13  Seok-Yong.
Peripheral blood and airway tissue expression of transforming growth factor β by neutrophils in asthmatic subjects and normal control subjects  Hong Wei.
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience  C.R.
Uta Griesenbach, A. Christopher Boyd  Journal of Cystic Fibrosis 
Engraftment of Bone Marrow–derived Stem Cells to the Lung in a Model of Acute Respiratory Infection by Pseudomonas aeruginosa  Joanna Rejman, Carla Colombo,
Presentation transcript:

BIIL 284 reduces neutrophil numbers but increases P BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs  Gerd Döring, Alessandra Bragonzi, Moira Paroni, Firdevs-Fatma Aktürk, Cristina Cigana, Annika Schmidt, Deirdre Gilpin, Susanne Heyder, Torsten Born, Christina Smaczny, Martin Kohlhäufl, Thomas O.F. Wagner, Michael R. Loebinger, Diana Bilton, Michael M. Tunney, J. Stuart Elborn, Gerald B. Pier, Michael W. Konstan, Martina Ulrich  Journal of Cystic Fibrosis  Volume 13, Issue 2, Pages 156-163 (March 2014) DOI: 10.1016/j.jcf.2013.10.007 Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Bacterial quantification of P. aeruginosa DNA in the blood of a CF patient. TaqMan quantitative PCR was performed on DNA extracts of blood samples from CF patients, patients with non-CF bronchiectasis and healthy individuals. A. Agarose gel with qPCR product results of 16 CF patients revealing one positive sample with the amplification of the 200bp PA4331. 17: positive control (plasmid DNA including PA 4331, spiked with human DNA), 18: negative control (human DNA) 19: water control; B. qPCR amplification curves of the PA4331 and controls in the blood sample from CF patient #4. Red bar: cut-off of the assay. Journal of Cystic Fibrosis 2014 13, 156-163DOI: (10.1016/j.jcf.2013.10.007) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 BIIL 284 treatment changes the ratio between phagocytic cells and bacteria in lungs of mice infected with P. aeruginosa. A, B, BIIL 284 treatment decreases neutrophil but not macrophage numbers in bronchoalveolar lavage fluids (BALF) of infected mice. Groups of six to eight mice were challenged intratracheally with 5×105cfu of P. aeruginosa and 1h thereafter with different doses of BIIL 284. Neutrophil (A) and macrophage (B) numbers were determined in BALF of infected animals and uninfected controls by routine methods. C, BIIL 284 promotes growth of P. aeruginosa in lungs of infected mice. Groups of seven to 14 mice were challenged with different doses of BIIL 284 1h before intratracheal challenge with 5×105cfu of P. aeruginosa and bacterial colony forming units (cfu) were determined in total lung tissues of infected and uninfected animals after 24h using routine methods. D, BIIL 284 treatment changes the ratio of P. aeruginosa cfuscfu/neutrophils. Kendall's rank-correlation, † was used to assess the relationship between the ordinal variable BIIL 284 and the continuous variable ratio (cfu/neutrophils). *p≤0.05; **p<0.01. Journal of Cystic Fibrosis 2014 13, 156-163DOI: (10.1016/j.jcf.2013.10.007) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 BIIL 284 treatment increases lung inflammation infected mice. A, BIIL 284 promotes increased cytokine expression in lungs of infected mice. The chemokines IL-1β, KC, MIP-2 and JE were quantitatively determined by ELISA in lung homogenates of uninfected mice, treated with a single dose of 100mg/kg BIIL 284, and in untreated infected mice (CTR) and in infected mice, treated with the doses of 0.3, 50 and 100mg/kg BIIL 284. *p≤0.05; **p<0.01; p<0.001. Journal of Cystic Fibrosis 2014 13, 156-163DOI: (10.1016/j.jcf.2013.10.007) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 4 BIIL 284 treatment increases P. aeruginosa translocation via the alveoli in infected mice. BIIL 284 treatment allows P. aeruginosa to reach the airway epithelium. P. aeruginosa was stained with a specific antibody in 5μm lung tissue sections of infected mice treated with a single dose of 100mg/kg BIIL 284 (A, B), or 50mg/kg of BIIL 284 (C, D) or untreated animals (E, F). Br: Bronchus, P: Periphery, S: septa, red color and arrow: P. aeruginosa. Original magnifications: A, C, E ×100; insets B, D, F ×1000. Journal of Cystic Fibrosis 2014 13, 156-163DOI: (10.1016/j.jcf.2013.10.007) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions